Author Description

<p> The pace of globalization has significantly accelerated since the end of the Cold War Era in 1989. These changes profoundly affected health care systems worldwide. Health policy makers increasingly started facing new harsh challenges in their uneasy task to provide universal health coverage and decent equity of access to medical services. Among the most prominent demand-side issues are extended longevity joined with population aging, rise of non-communicable diseases, and growing patient expectations. Supply-side causes are gains in societal welfare and living standards, technological innovation in medicine and continuing rapid urbanization in developing world regions. Successful insurance-based risk sharing agreements made drug dispensing and medical service provision cheap or virtually free at the point of consumption in most OECD and many middle-income countries. Coupled with massive build-up of workforce capacities and strengthening of primary care and hospital networks, all these factors contributed to the “supplier induced demand” phenomenon.</p><p><br></p><p>There is straightforward historical evidence of long-term growth in pharmaceutical and overall health spending both in absolute and GDP% terms worldwide. The accumulated constraints deriving from skyrocketing costs of care were felt in many areas of clinical medicine even among the richest societies. Cardinal examples of expensive and hardly affordable therapeutic areas are orphan drugs indicated to treat rare diseases and targeted biologicals used in autoimmune disorders and cancer. Last but not least, is troubled and frequently denied access to even essential generic pharmaceuticals still taking place in many nations. This appears to be particularly the case among the world's poor and under-served citizens residing in rural and suburban areas of low- and middle-income countries. To a large extent, these difficulties are worsened by lack of evidence-based resource allocation strategies and less susta